Yotam Arens1, Michael Gaisa2, Stephen E Goldstone3, Yuxin Liu4, Juan Wisnivesky1, Carlie S Sigel5, Talia H Swartz2, Keith Sigel1. 1. Division of General Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: The progression rate and predictors of anal dysplastic lesions to squamous cell carcinoma of the anus remain unclear. Characterizing these parameters may help refine anal cancer screening guidelines. OBJECTIVE: This study aimed to determine the rate of progression of high-grade anal dysplasia to invasive carcinoma in HIV-infected persons. DESIGN: Using the Surveillance, Epidemiology, and End Results database linked to Medicare claims from 2000 to 2011, we identified HIV-infected subjects with incident anal intraepithelial neoplasia III. To estimate the rate of progression of anal intraepithelial neoplasia III to invasive cancer, we calculated the cumulative incidence of anal cancer in this cohort. We then fitted Poisson models to evaluate the potential risk factors for incident anal cancer. SETTINGS: This is a population-based study. PATIENTS: Included were 592 HIV-infected subjects with incident anal intraepithelial neoplasia III. MAIN OUTCOME MEASURES: The primary outcome measured was incident squamous cell carcinoma of the anus. RESULTS: Study subjects were largely male (95%) with a median age of 45.7 years. Within the median follow-up period of 69 months, 33 subjects progressed to anal cancer. The incidence of anal cancer was 1.2% (95% CI, 0.7%-2.5%) and 5.7% (95% CI, 4.0%-8.1%) at 1 and 5 years, following a diagnosis of anal intraepithelial neoplasia III. Risk of progression did not differ by anal intraepithelial neoplasia III treatment status. On unadjusted analysis, black race (p = 0.02) and a history of anogenital condylomata (p = 0.03) were associated with an increased risk of anal cancer incidence, whereas prior anal cytology screening was associated with a decreased risk (p = 0.04). LIMITATIONS: The identification of some incident cancer episodes used surrogate measures. CONCLUSIONS: In our population-based cohort of HIV-infected subjects with long-term follow-up, the risk of progression from anal intraepithelial neoplasia III to anal squamous cell carcinoma was higher than reported in other studies and was not associated with the receipt of anal intraepithelial neoplasia III treatment. See Video Abstract at http://links.lww.com/DCR/A933.
BACKGROUND: The progression rate and predictors of anal dysplastic lesions to squamous cell carcinoma of the anus remain unclear. Characterizing these parameters may help refine anal cancer screening guidelines. OBJECTIVE: This study aimed to determine the rate of progression of high-grade anal dysplasia to invasive carcinoma in HIV-infectedpersons. DESIGN: Using the Surveillance, Epidemiology, and End Results database linked to Medicare claims from 2000 to 2011, we identified HIV-infected subjects with incident anal intraepithelial neoplasia III. To estimate the rate of progression of anal intraepithelial neoplasia III to invasive cancer, we calculated the cumulative incidence of anal cancer in this cohort. We then fitted Poisson models to evaluate the potential risk factors for incident anal cancer. SETTINGS: This is a population-based study. PATIENTS: Included were 592 HIV-infected subjects with incident anal intraepithelial neoplasia III. MAIN OUTCOME MEASURES: The primary outcome measured was incident squamous cell carcinoma of the anus. RESULTS: Study subjects were largely male (95%) with a median age of 45.7 years. Within the median follow-up period of 69 months, 33 subjects progressed to anal cancer. The incidence of anal cancer was 1.2% (95% CI, 0.7%-2.5%) and 5.7% (95% CI, 4.0%-8.1%) at 1 and 5 years, following a diagnosis of anal intraepithelial neoplasia III. Risk of progression did not differ by anal intraepithelial neoplasia III treatment status. On unadjusted analysis, black race (p = 0.02) and a history of anogenital condylomata (p = 0.03) were associated with an increased risk of anal cancer incidence, whereas prior anal cytology screening was associated with a decreased risk (p = 0.04). LIMITATIONS: The identification of some incident cancer episodes used surrogate measures. CONCLUSIONS: In our population-based cohort of HIV-infected subjects with long-term follow-up, the risk of progression from anal intraepithelial neoplasia III to anal squamous cell carcinoma was higher than reported in other studies and was not associated with the receipt of anal intraepithelial neoplasia III treatment. See Video Abstract at http://links.lww.com/DCR/A933.
Authors: Teresa M Darragh; Terence J Colgan; J Thomas Cox; Debra S Heller; Michael R Henry; Ronald D Luff; Timothy McCalmont; Ritu Nayar; Joel M Palefsky; Mark H Stoler; Edward J Wilkinson; Richard J Zaino; David C Wilbur Journal: Arch Pathol Lab Med Date: 2012-06-28 Impact factor: 5.534
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: Michael J Silverberg; Bryan Lau; Amy C Justice; Eric Engels; M John Gill; James J Goedert; Gregory D Kirk; Gypsyamber D'Souza; Ronald J Bosch; John T Brooks; Sonia Napravnik; Nancy A Hessol; Lisa P Jacobson; Mari M Kitahata; Marina B Klein; Richard D Moore; Benigno Rodriguez; Sean B Rourke; Michael S Saag; Timothy R Sterling; Kelly A Gebo; Natasha Press; Jeffrey N Martin; Robert Dubrow Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: Michael Gaisa; Fanny Ita-Nagy; Keith Sigel; Yotam Arens; Mary Ann Hennessy; Gabriela Rodriguez-Caprio; Michael Mullen; Judith A Aberg; Michelle Cespedes Journal: Clin Infect Dis Date: 2016-11-09 Impact factor: 9.079
Authors: Edgar P Simard; Meg Watson; Mona Saraiya; Christina A Clarke; Joel M Palefsky; Ahmedin Jemal Journal: Cancer Date: 2013-07-16 Impact factor: 6.860
Authors: J Michael Berry; Naomi Jay; Ross D Cranston; Teresa M Darragh; Elizabeth A Holly; Mark L Welton; Joel M Palefsky Journal: Int J Cancer Date: 2013-09-14 Impact factor: 7.396
Authors: William C Mathews; Wollelaw Agmas; Edward R Cachay; Bard C Cosman; Christopher Jackson Journal: PLoS One Date: 2014-08-07 Impact factor: 3.240
Authors: G A Binda; G Gagliardi; I Dal Conte; M Verra; P Cassoni; E Cavazzoni; E Stocco; S Delmonte; P De Nardi; L Sticchi; M Mistrangelo Journal: Tech Coloproctol Date: 2019-06-26 Impact factor: 3.781
Authors: Jessica Wells; Lisa Flowers; C Christina Mehta; Rasheeta Chandler; Robert Knott; Marcia McDonnell Holstad; Deborah Watkins Bruner Journal: AIDS Patient Care STDS Date: 2022-06-21 Impact factor: 5.944
Authors: Richard Silvera; Tyler Martinson; Michael M Gaisa; Yuxin Liu; Ashish A Deshmukh; Keith Sigel Journal: AIDS Date: 2021-11-01 Impact factor: 4.177
Authors: Carmen Hidalgo-Tenorio; Concepción Gil-Anguita; Miguel Angel López Ruz; Mohamed Omar; Javier López-Hidalgo; Juan Pasquau Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240
Authors: Carmen Hidalgo-Tenorio; Carmen Maria García-Martínez; Juan Pasquau; Mohamed Omar-Mohamed-Balgahata; Miguel López-Ruz; Javier López-Hidalgo; Concepción Gil-Anguita Journal: PLoS One Date: 2021-02-03 Impact factor: 3.240